The Myeloma Beacon » Defibrotide

Defibrotide

By: Funmi Adewale; Published: February 4, 2010 @ 1:18 pm | Comments Disabled

Brand Name:
Generic Name:	defibrotide
Code Name:
Company:	Gentium SpA
FDA Clinical Phase:	1/2

Description:
Defibrotide is an anticoagulant (a drug that prevents blood clotting) that may make myeloma cells more susceptible to chemotherapy. It is not an anti-tumor drug and only has a significant effect on myeloma when combined with cancer-fighting drugs. Defibrotide may decrease blood clotting and nerve damage caused by certain myeloma treatments. In combination with granulocyte colony-stimulating factor (G-CSF), defibrotide has been shown to significantly increase stem cell production. Defibrotide has also demonstrated an ability to treat hepatic veno-occulusive disease (VOD), a life-threatening complication of stem cell transplantation that is marked by blocked veins in the liver.

Clinical Trials:
For a list of clinical trials studying defibrotide for the treatment of multiple myeloma, see ClinicalTrials.gov ^[1].

Web site for defibrotide: http://www.gentium.it/Defibrotide.aspx ^[2]

Article printed from The Myeloma Beacon: https://myelomabeacon.org

URL to article: https://myelomabeacon.org/resources/2010/02/04/defibrotide/

URLs in this post:

[1] ClinicalTrials.gov: http://clinicaltrials.gov/ct2/results?term=&recr=&rslt=&type=&cond=multiple+myeloma&intr=defibrotide&outc=&lead=&spons=&id=&state1=&cntry1=&state2=&cntry2=&state3=&cntry3=&locn=&gndr=&rcv_s=&rcv_e=&lup_s=&lup_e=

[2] http://www.gentium.it/Defibrotide.aspx: http://www.gentium.it/Defibrotide.aspx

Click here to print.